These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26340698)

  • 1. Neutralization of inhibitory antibodies and restoration of therapeutic ADAMTS-13 activity levels in inhibitor-treated rats by the use of defined doses of recombinant ADAMTS-13.
    Plaimauer B; Schiviz A; Kaufmann S; Höllriegl W; Rottensteiner H; Scheiflinger F
    J Thromb Haemost; 2015 Nov; 13(11):2053-62. PubMed ID: 26340698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism underlying severe deficiency of plasma ADAMTS-13 activity in immune thrombotic thrombocytopenic purpura.
    Zheng XL
    J Thromb Haemost; 2024 May; 22(5):1358-1365. PubMed ID: 38360215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.
    Shelat SG; Smith P; Ai J; Zheng XL
    J Thromb Haemost; 2006 Aug; 4(8):1707-17. PubMed ID: 16879212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel flow-based assay reveals discrepancies in ADAMTS-13 inhibitor assessment as compared with a conventional clinical static assay.
    Grillberger R; Gruber B; Skalicky S; Schrenk G; Knöbl P; Plaimauer B; Turecek PL; Scheiflinger F; Rottensteiner H
    J Thromb Haemost; 2014 Sep; 12(9):1523-32. PubMed ID: 25040659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.
    Thomas MR; de Groot R; Scully MA; Crawley JT
    EBioMedicine; 2015 Aug; 2(8):942-52. PubMed ID: 26425702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura.
    Tersteeg C; Schiviz A; De Meyer SF; Plaimauer B; Scheiflinger F; Rottensteiner H; Vanhoorelbeke K
    Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2336-42. PubMed ID: 26338302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura.
    Scheiflinger F; Knöbl P; Trattner B; Plaimauer B; Mohr G; Dockal M; Dorner F; Rieger M
    Blood; 2003 Nov; 102(9):3241-3. PubMed ID: 12855569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies.
    Plaimauer B; Kremer Hovinga JA; Juno C; Wolfsegger MJ; Skalicky S; Schmidt M; Grillberger L; Hasslacher M; Knöbl P; Ehrlich H; Scheiflinger F
    J Thromb Haemost; 2011 May; 9(5):936-44. PubMed ID: 21294825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences.
    Feys HB; Liu F; Dong N; Pareyn I; Vauterin S; Vandeputte N; Noppe W; Ruan C; Deckmyn H; Vanhoorelbeke K
    J Thromb Haemost; 2006 May; 4(5):955-62. PubMed ID: 16689741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura.
    Ferrari S; Palavra K; Gruber B; Kremer Hovinga JA; Knöbl P; Caron C; Cromwell C; Aledort L; Plaimauer B; Turecek PL; Rottensteiner H; Scheiflinger F
    Haematologica; 2014 Apr; 99(4):779-87. PubMed ID: 24241492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.
    Tsai HM; Lian EC
    N Engl J Med; 1998 Nov; 339(22):1585-94. PubMed ID: 9828246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical assessment of a new recombinant ADAMTS-13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura.
    Kopić A; Benamara K; Piskernik C; Plaimauer B; Horling F; Höbarth G; Ruthsatz T; Dietrich B; Muchitsch EM; Scheiflinger F; Turecek M; Höllriegl W
    J Thromb Haemost; 2016 Jul; 14(7):1410-9. PubMed ID: 27371116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura.
    Bettoni G; Palla R; Valsecchi C; Consonni D; Lotta LA; Trisolini SM; Mancini I; Musallam KM; Rosendaal FR; Peyvandi F
    J Thromb Haemost; 2012 Aug; 10(8):1556-65. PubMed ID: 22672482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibodies enhance ADAMTS-13 clearance in patients with immune thrombotic thrombocytopenic purpura.
    Underwood MI; Alwan F; Thomas MR; Scully MA; Crawley JTB
    J Thromb Haemost; 2023 Jun; 21(6):1544-1552. PubMed ID: 36813118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of N-glycan mediated shielding of ADAMTS-13 on the binding of pathogenic antibodies in immune thrombotic thrombocytopenic purpura.
    Postmus T; Graça NAG; Ferreira de Santana J; Ercig B; Langerhorst P; Luken B; Joly BS; Vanhoorelbeke K; Veyradier A; Coppo P; Voorberg J
    J Thromb Haemost; 2023 Dec; 21(12):3402-3413. PubMed ID: 37633643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thrombotic Thrombocytopenic Purpura --Pathophysiology and Assays of ADAMTS13 Activity].
    Kato S; Fujimura Y
    Rinsho Byori; 2015 Oct; 63(10):1228-36. PubMed ID: 26897861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies.
    Tersteeg C; Verhenne S; Roose E; Schelpe AS; Deckmyn H; De Meyer SF; Vanhoorelbeke K
    Expert Rev Hematol; 2016; 9(2):209-21. PubMed ID: 26581428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombotic thrombocytopenic purpura and anti-thrombotic therapy targeted to von Willebrand factor.
    Zhou Z; Dong JF
    Curr Vasc Pharmacol; 2012 Nov; 10(6):762-6. PubMed ID: 22022775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine.
    Böhm M; Betz C; Miesbach W; Krause M; von Auer C; Geiger H; Scharrer I
    Br J Haematol; 2005 Jun; 129(5):644-52. PubMed ID: 15916687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura.
    Camilleri RS; Cohen H; Mackie IJ; Scully M; Starke RD; Crawley JT; Lane DA; Machin SJ
    J Thromb Haemost; 2008 Feb; 6(2):331-8. PubMed ID: 18031293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.